Actively Recruiting
Ruxolitinib Treatment in Inclusion Body Myositis
Led by Assistance Publique - Hôpitaux de Paris · Updated on 2025-10-03
80
Participants Needed
16
Research Sites
171 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Refer to the "Detailed Description" section.
CONDITIONS
Official Title
Ruxolitinib Treatment in Inclusion Body Myositis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 45 years or older
- Effective contraception during the trial for fertile women of childbearing age
- Diagnosed with IBM by: finger flexor or quadriceps weakness; muscle biopsy showing endomysial inflammation; and biopsy showing invasion of nonnecrotic muscle fibers or rimmed vacuoles
- Able to walk 6 minutes without assistance from another person (can use assistive devices like canes or walkers)
- Provided informed consent to participate, possibly with help from a trusted person
You will not qualify if you...
- Pregnant or breastfeeding
- Under guardianship, curatorship, safeguard of justice, or deprived of liberty
- Cognitive disorders or unable to understand the study or give consent
- Quadriceps muscle strength less than or equal to 1 on manual muscle testing
- Forced vital capacity or forced expiratory volume less than 50% of predicted
- Using immunomodulatory drugs including previous JAK inhibitors, or muscle anabolic/catabolic medications
- Received live vaccine within 4 weeks before treatment
- Comorbidities contraindicating ruxolitinib including severe lipid abnormalities, severe kidney or liver impairment, cytopenia, recent serious cardiovascular or thromboembolic events, heavy smoking history, recent cancer, very high cardiovascular risk, history of Stevens-Johnson or Lyell's syndrome
- Active COVID-19 infection (can be included after recovery)
- Any medical condition limiting study participation
- Need for medications incompatible with ruxolitinib
- Allergy to ruxolitinib or its ingredients
- Not covered by social security or medical aid
- Expected inability to complete all visits, treatments, and assessments
- Participation in another clinical trial involving medical products or devices recently or concurrently
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 16 locations
1
Hôpital Pellegrin - Tripode, CHU de Bordeaux
Bordeaux, France, France, 33076
Active, Not Recruiting
2
Hôpital Pierre Wertheimer, CHU de Lyon
Bron, France, France, 69500
Active, Not Recruiting
3
CHU Caen Normandie
Caen, France, France, 14000
Active, Not Recruiting
4
Hôpital Henri-Mondor, APHP
Créteil, France, France, 94010
Actively Recruiting
5
Hôpital Raymond Poincaré, APHP
Garches, France, France, 92380
Active, Not Recruiting
6
Hôpital Roger Salengro, CHU de Lille
Lille, France, France, 59037
Not Yet Recruiting
7
Hôpital Dupuytren, CHU de Limoges
Limoges, France, France, 87000
Active, Not Recruiting
8
Hôpital de la Timone, APHM
Marseille, France, France, 13005
Not Yet Recruiting
9
CHU Nancy
Nancy, France, France, 54035
Active, Not Recruiting
10
Hôtel-Dieu, CHU Nantes
Nantes, France, France, 44093
Not Yet Recruiting
11
Hôpital Pasteur, CHU de Nice
Nice, France, France, 06001
Actively Recruiting
12
Hôpital Pitié-Salpêtrière, APHP
Paris, France, France, 75013
Active, Not Recruiting
13
Hôpital Christian Cabrol, CHU Reims
Reims, France, France, 51100
Active, Not Recruiting
14
Hôpital Bellevue, CHU Saint-Etienne
Saint-Etienne, France, France, 42270
Active, Not Recruiting
15
Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg
Strasbourg, France, France, 67089
Not Yet Recruiting
16
Hôpital Pierre-Paul Riquet, CHU de Toulouse
Toulouse, France, France, 31059
Not Yet Recruiting
Research Team
F
François Jérôme AUTHIER, Pr
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here